Uppsalalaan 17
3rd & 4th floor
Utrecht 3584 CT
Netherlands
31 30 253 8800
https://www.merus.nl
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 172
Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
---|---|---|---|---|
Dr. Sven Ante Lundberg M.D. | CEO, President & Executive Director | 953.06k | N/D | 1963 |
Mr. Gregory D. Perry | Chief Financial Officer | 63.76k | N/D | 1960 |
Mr. Peter B. Silverman J.D. | EVP, Company Secretary, COO, General Counsel, Chief Intellectual Property Officer & Head of US Legal | 601.19k | 947.4k | 1978 |
Dr. Hui Liu Ph.D. | Chief Business Officer, Executive VP & Head of Merus U.S. | 597.7k | N/D | 1967 |
Dr. Andrew Joe M.D. | Chief Medical Officer & Senior VP | 692.74k | N/D | 1967 |
Dr. Hennie Hoogenboom | Co-Founder and Scientific Advisor | N/D | N/D | N/D |
Harry Shuman | Chief Accounting Officer | N/D | N/D | N/D |
Mr. Cornelis Adriaan de Kruif Ph.D. | CTO & Executive VP | 350.85k | N/D | 1965 |
Dr. Cecilia Anna Wilhelmina Geuijen Ph.D. | Chief Scientific Officer & Senior VP | N/D | N/D | N/D |
Kathleen Farren | IR & Corporate Communications Officer | N/D | N/D | N/D |
Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; collaboration with Incyte Corporation for the development of MCLA-145; and collaboration with Gilead Sciences, Inc. to discover novel antibody-based trispecific T-cell engagers. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.
La calificación ISS Governance QuickScore de Merus N.V. a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.